Immunization for protection of the reproductive tract: a review
- PMID: 12148540
- DOI: 10.1034/j.1600-0897.2002.01099.x
Immunization for protection of the reproductive tract: a review
Abstract
Problem: Local application of non-replicating antigens to the female reproductive tract is ineffective in stimulating the common mucosal immune system, and induces only weak genital antibody responses. Studies of immune responses to genital infections such as gonorrhea also support the concept that, lacking mucosal immune inductive sites, the reproductive tract is ill-equipped to mount effective immune responses.
Method of study: Intranasal (i.n.) and intravaginal (i.vag.) routes of immunization of mice with a protein antigen coupled to cholera toxin (CT) B subunit, or genetically engineered as chimeric proteins with the A2/B sunbunits of CT or type II heat-labile enterotoxin, were compared for their ability to induce specific antibody responses in vaginal fluids, saliva, and serum.
Results: Mice immunized i.n. developed substantially stronger vaginal immunoglobulin A (IgA) and immunoglobulin G (IgG) and serum IgG and IgA antibodies, than those immunized i.vag. which also failed to develop salivary antibodies. Vaginal antibody responses induced i.n. persisted for at least 1 year, and were recallable by booster immunization after a prolonged period.
Conclusions: Such alternative strategies for inducing potent genital antibody responses offer the prospect of prophylactic immunization against genital infections. Further studies are required to evaluate their applicability to humans, and to comprehend the cellular and molecular mechanisms involved in delivering effective immune responses to the reproductive tracts.
Similar articles
-
Generation of female genital tract antibody responses by local or central (common) mucosal immunization.Infect Immun. 2000 Oct;68(10):5539-45. doi: 10.1128/IAI.68.10.5539-5545.2000. Infect Immun. 2000. PMID: 10992451 Free PMC article.
-
Mucosal immunity in the genital tract: prospects for vaccines against sexually transmitted diseases--a review.Am J Reprod Immunol. 1999 Jul;42(1):58-63. doi: 10.1111/j.1600-0897.1999.tb00466.x. Am J Reprod Immunol. 1999. PMID: 10429768 Review.
-
Microencapsulated IL-12 Drives Genital Tract Immune Responses to Intranasal Gonococcal Outer Membrane Vesicle Vaccine and Induces Resistance to Vaginal Infection with Diverse Strains of Neisseria gonorrhoeae.mSphere. 2023 Feb 21;8(1):e0038822. doi: 10.1128/msphere.00388-22. Epub 2022 Dec 20. mSphere. 2023. PMID: 36537786 Free PMC article.
-
Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus.Vaccine. 1995 Nov;13(16):1589-95. doi: 10.1016/0264-410x(95)00100-f. Vaccine. 1995. PMID: 8578847
-
Immunologic uniqueness of the genital tract: challenge for vaccine development.Am J Reprod Immunol. 2005 May;53(5):208-14. doi: 10.1111/j.1600-0897.2005.00267.x. Am J Reprod Immunol. 2005. PMID: 15833098 Review.
Cited by
-
A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment.PLoS One. 2011 Jan 6;6(1):e15861. doi: 10.1371/journal.pone.0015861. PLoS One. 2011. PMID: 21253014 Free PMC article.
-
Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C.Infect Immun. 2004 May;72(5):2753-61. doi: 10.1128/IAI.72.5.2753-2761.2004. Infect Immun. 2004. PMID: 15102785 Free PMC article.
-
Mucosal delivery of CpG oligodeoxynucleotides expands functional dendritic cells and macrophages in the vagina.Immunology. 2005 Feb;114(2):213-24. doi: 10.1111/j.1365-2567.2004.02081.x. Immunology. 2005. PMID: 15667566 Free PMC article.
-
Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back.Front Immunol. 2022 Apr 25;13:849515. doi: 10.3389/fimmu.2022.849515. eCollection 2022. Front Immunol. 2022. PMID: 35547736 Free PMC article. Review.
-
Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes.J Virol. 2006 Jun;80(11):5283-91. doi: 10.1128/JVI.02013-05. J Virol. 2006. PMID: 16699008 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous